Novel 8-heterocyclyl xanthine derivatives in drug development - An update

Expert Opinion on Drug Discovery

Volumn 2, Issue 9, 2007, Pages 1161-1183

  Baraldi, Pier G ^a   Fruttarolo, Francesca ^a   Tabrizi, Mojgan A ^a   Romagnoli, Romeo ^a   Preti, Delia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

8 heterocyclyl xanthines; A1 antagonist; A2B antagonists; Adenosine receptors; Alzheimer's disease; Asthma; Atherosclerosis diabetes Dipeptidyl pepridase IV inhibitors; Liver X receptor agonists

Indexed keywords

1 PROPYL 8 4 SULFOPHENYLXANTHINE; 1,3 DIPROPYL 8 [2 (5,6 EPOXYNORBORNYL)]XANTHINE; 2 (3,4 DIMETHOXYPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; 3 ISOBUTYL 8 PYRROLIDINOXANTHINE; 3 METHYL 1 PROPYL 8 [4 [6 CHLOROPYRIDAZIN 3(2H) ONE 2 YL]BUTYL]XANTHINE; 8 (3 AMINO PIPERIDIN 1 YL) 7 (BUT 2 INYL)XANTHINE DERIVATIVE; 8 (4 CARBOXYMETHOXYPHENYL) 1,3 DIPROPYLXANTHINE; 8 ([1,4]DIAZEPAN 1 YL)XANTHINE DERIVATIVE; 8 (PIPERAZINE 1 YL)XANTHINE DERIVATIVE; 8 [4 (4 BENZYLPIPERAZIDE 1 SULFONYL)PHENYL] 1 PROPYLXANTHINE; 8 HETEROCYCLIC XANTHINE DERIVATIVE; 8 PIPERIDINOXANTHINE DERIVATIVE; 8 PYRROLIDINOXANTHINE DERIVATIVE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; CORTICOSTEROID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENPROFYLLINE; LIVER X RECEPTOR; MRE 2028 F20; MRE 2029 F20; MRE 2030 F20; N (3,4 DIMETHOXYPHENYL) 2 [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YL OXI]ACETAMIDE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N BENZO[1,3]DIOXOL 5 YL 2 [5 (2,6 DIOXO) 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YL OXI]ACETAMIDE; PSB 1115; RETINOID X RECEPTOR; THEOBROMINE; THEOPHYLLINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BINDING AFFINITY; BRONCHODILATATION; CLINICAL TRIAL; COMA; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIURESIS; DRUG RECEPTOR BINDING; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART EDEMA; HEART PROTECTION; HUMAN; INSOMNIA; LUNG EDEMA; MIGRAINE; MONOTHERAPY; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RENAL PROTECTION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 34848915118     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.9.1161     Document Type: Review

References (65)

1. BRUNS RF: Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. (1981) 30(4):325-333.
2. DALY JW: Adenosine receptors: targets for future drugs. J. Med. Chem. (1982) 25(3):197-207.
3. LAINEZ MJ, GALVAN J, HERAS J, VILA C: Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol. (2007) 14(3):269-275.
4. 2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. (2004) 308(1):358-366.
5. BARNES PJ: Drugs for asthma. Br J. Pharmacol. (2006) 147(1):S297-S303.
6. BOSWELL-SMITH V, CAZZOLA M, PAGE CP: Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. (2006) 117(6):1237-1243.
7. BOSWELL-SMITH V, SPINA D, PAGE CP: Phosphodiesterase inhibitors. Br. J. Pharmacol. (2006) 147(1):S252-S257.
8. BARNES PJ: Reduced histone deacetylase in COPD: clinical implications. Chest (2006) 129(1):151-155.
9. JACOBSON KA, GAO ZG: Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov. (2006) 5(3):247-264.
10. EL-SABBAGH 0I, EL-SADEK ME, EL,KALYOUBI S, ISMAIL I: Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivatives. Arch. Pharm. Chem. Life Sci. (2007) 340(1):26-31.
11. VLOK N, MALAN SF, CASTAGNOLI NJR, BERGH JJ, PETZER JP: Inhibition of monoamine oxidase B by analogues of the adenosine A2Δ receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg. Med. Chem. (2006) 14(10):3512-3521.
12. SUZUKI H, SAWANISHI H, YAMAMOTO K, YOKOGAWA K, MIYAMOTO K: Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-phenyl[i]condensed-purines. Chem. Pharm. Bull. (2001) 49(2):188-191.
13. WANG Y, CHACKALAMANNIL S, HU Z et al.: Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(21):3149-3152.
14. COTTAM HB, SHIH H, TEHRANI LR, WASSON DB, CARSON DA. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of TNF. J. Med. Chem. (1996) 39(1):2-9.
15. KLINGER M, FREISSMUTH M, NANOFF C: Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal. (2002) 14(2):99-108.
16. DALY JW, BUTTS-LAMB P, PADGETT W: Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. (1983) 3(1):69-80.
17. STEHLE JH, RIVKEES SA, LEE JJ, WEAVER DR, DEEDS JD, REPPERT SM: Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol. Endocrinol. (1992) 6(3):384-393.
18. 2B receptors. Pharmacol. Rev. (1997) 49(4):381-402.
19. FREDHOLM BB, IJZERMAN AP, JACOBSON KA, KLOTZ KN, LINDEN J: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53(4):527-552.
20. 2B adenosine receptors. Curr. Top. Med. Chem. (2003) 3(4):427-443.
21. 2B adenosine receptor antagonists: recent developments. Mini Pev. Med. Chem. (2005) 5(12):1053-1060.
22. RORKE S, HOLGATE ST. Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Med. (2002) 1(2):99-105.
23. 2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J. Immunol. (2004) 172(12):7726-7733.
24. SANDS WA, PALMER TM: Adenosine receptors and the control of endothelial cell function in inflammatory desease. Immunol. Lett. (2005) 101(1):1-11.
25. LIVINGSTON M, HEANEY LG, ENNIS M: Adenosine, inflammation and asthma-a review. Inflamm. Res. (2004) 53(5):171-178.
26. 2B receptor ligands. Med. Res. Rev. (2006) 26(5):667-698.
27. 2B receptors as therapeutic targets. Drug Dev. Res. (1998) 45(3):198-206.
28. 2B adenosine receptors ofxanthine derivatives substituted at the 1, 3-, 7-, and 8-positions. J. Med. Chem. (2002) 45(11):2131-2138.
29. 2B adenosine receptor. J. Med. Chem. (2000) 43(6):1165-1172.
30. 2B adenosine receptor antagonists. J. Med Chem. (2004) 47(6):1434-1447.
31. 2B receptor antagonist for the potential treatment of asthma. Bioorg. Med. Chem. Lett. (2005) 15(3):609-612.
32. 2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16(2):302-306.
33. 2B adenosine receptor antagonists. J. Med. Chem. (2006) 49(12):3682-3692.
34. 2B adenosine receptor. J. Med. Chem. (2006) 49(1):282-299.
35. 2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16(14):3642-3645.
36. 2B receptor antagonists. J. Med. Chem. (2006) 49(14):4384-4391.
37. 2B receptor antagonist 3-isobutyl-8-pyrrofidinoxanthine (IPDX). Biochem. Pharmacol. (2001) 62(9):1163-1173.
38. BAZIARD-MOUYSSET G, RACHED A, YOUNES S et al.: Synthesis and in vitro bronchospasmolyEic activity of 8-aryl, heteroaryl or arylalkyl theophyllines. Eur. J. Med. Chem. (1995) 30(3):253-260.
39. REGNIER GL, GUILLONNEAU CG, DUHAULT JL, TISSERAND FP, SAINT-ROMAS G, HOLSTORP SM: New xanthine derivatives with potent and long lasting anti-bronchoconstrictive activity. Eur. J. Med. Chem. (1987) 22(3):243-250.
40. PROFIRE L, BUMBU GG, COSTULEANU M, DANILA G, VASILE C:Thermal and pharmacological characterization of some new bis-xanthine derivatives. Termochimica Acta (2002) 381(1):19-29.
41. BERK B, AKGUN H, EROL K, SIRMAGUL B, GAO Z-G, JACOBSON KA: New 8-substituted xanthine derivatives as bronchodilators. Farmaco (2005) 60(11-12):974-980.
42. MÜLLER CE: A1 adenosine receptors and their ligands: overview and recent developments. Farmaco (2001) 56(1):77-80.
43. KIESMAN WF, ZHAO J, CONLON PR: Potent and orally bioavailable 8-bicyclo[2.2.2]octrylxanthines as adenosine A1 receptor antagonists. J. Med. Chem. (2006) 49(24):7119-7131.
44. YUZLENKO O, KIEC'-KONONOVICZ K: Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr. Med. Chem. (2006) 13(30):3609-3625.
45. DHALLA AV, SHRYOCK JC, SHREENIWAS R, BELARDINELLI L: Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem. (2003) 3(4):369-385.
46. PFISTER JR, BELARDINELLI L, LEE G et al.: Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-(Upropyl-8-[2-(5,6-epoxynorbomyl)]-xanthine. J. Med. Chem. (1997) 40(12):1773-1778.
47. KIESMAN WF, ZHAO J, CONLON PR et al.: Norbornyllactone-substituted xanthines as adenosine A1 receptor antagonists. Bioorg. Med. Chem. (2006) 14(11):3654-3661.
48. STRAPPAGHETTI G, CORSANO S, BARBARO R, GIANNACCINI G, BETTI L: Structure-activity relationships in a series of 8-substituted xanthines as A1-adenosine receptor antagonists. Bioorg. Med. Chem. (2001) 9(3):575-583.
49. ILAS J, PECAR S, HOCKEMEYER J, EULER H, KIRFEL A, MULLER CE: Development of spin-labeled probes for adenosine receptors. J. Med. Chem. (2005) 48(6):2108-2114.
50. ENGEL M, HOFFMANN T, MANHART S et al.: Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. J. Mol. Biol. (2006) 355(4):768-783.
51. WEBER AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. (2004) 47(17):4135-4141.
52. KOLTERMAN OG, BUSE JB, FINEMAN MS et al.: Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. Clin. Endocrinol. Metab. (2003) 88(7):3082-3089.
53. AUGUSTYNS K, VAN DER VEKEN P, HAEMERS A. Inhibitors of proline-specific dipepridyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes. Expert Opin. Ther. Patents (2005) 15(10):1387-1407.
54. AUGUSTYNS K, VAN DER VEKEN P, SENTEN K, HAEMERS A: The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. (2005) 12(8):971-998.
55. KURUKULASURIYA R, ROHDE JJ, SZCZEPANKIEWICZ BG et al.: Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors. Bioorg, Med. Chem. Lett. (2006) 16(24):6226-6230.
56. LONGENECKER KL, STEWART KD, MADAR DJ et al.: Crystal structures of DPP-1V (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors. Biocbemistry (2006) 45(24):7474-7482.
57. SZCZEPANKIEWICZ BG, KURUKULASURIYA R: Aromatic heterocycle-based DPP-IV inhibitors: xanthines and related structural types. Curr. Top. Med. Chem. (2007) 7(6):569-578.
58. BRADLEY MN, TONTONOZ P: LXR: a nuclear receptor target for cardiovascular disease? Drug Discov. Today Ther. Strat. (2005) 2(2):97-103.
59. JAYE M: LXR agonists for the treament of atherosclerosis. Curr. Opin. Investig. Drugs (2003) 4(9):1053-1058.
60. BENNETT DJ, BROWN LD, COOKE AJ, EDWARDS AS: An update on non-steroidal liver X receptor agonists and their potential use in the treatment of atherosclerosis. Expert Opin. Ther. Patents (2006) 16(12):1673-1699.
61. CAO G, BALES KR, DEMATTOS RB, PAUL SM: Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. (2007) 4(2):179-184.
62. DELVECCHIO CJ, BILAN P, RADFORD K et al.: Liver X receptor stimulates cholesterol efflux and inhibits expression of pro-inflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. (2007) (In Press).
63. CHUU CP, KOKONTIS JM, HIIPAKKA RA, LIAO S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. (2007) (In Press).
64. CHUU CP, HIIPAKKA RA, KOKONTIS JM, FUKUCHI J, CHEN RY, LIAO S: Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. (2006) 66(13):6482-6486.
65. 2B adenosine receptor subtype. Curr. Med. Chem. (2006) 13(28):3467-3482.